Collaboration covers a CD44 cancer stem cell antibody.

Arius Research entered into a manufacturing supply and technology transfer agreement for its CD44 cancer stem cell antibody with Avid Bioservices. The company has already begun manufacturing a supply of the drug for clinical trials, which Arius plans to initiate in 2008.

Arius is advancing the formal preclinical toxicology program for its lead CD44 cancer stem cell program, an anticancer antibody targeting a novel epitope of CD44 found in breast, colon, and prostate cancers.

Previous articleLilly Taps Aveo to Ascertain Response to Its Oncology Drug Candidate
Next articleResearchers Identify Protein’s Role in Synapse Formation